Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the asthma and chronic obstructive pulmonary disease (COPD) market globally. Asthma & COPD are chronic respiratory diseases that are either genetically acquired or caused due to several environmental factors. These diseases are supposed to be non-curable, but may be controlled to a great extent with proper on-time diagnosis. The North America market for Asthma & COPD has been analyzed on the basis of drugs and devices used for these diseases. Key drugs employed for control and diagnosis of asthma and COPD may be classified on the basis of their types which include bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants.
The report highlights the adoption of COPD & Asthma Devices in North America. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The countries included in the report are U.S, Canada, Mexico and Rest of North America.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.